These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 26061101)

  • 1. Natural compound renews hope for diabetes and obesity therapeutic target.
    Merk D; Schubert-Zsilavecz M
    Future Med Chem; 2015; 7(7):833-5. PubMed ID: 26061101
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular matchmaking between the popular weight-loss herb Hoodia gordonii and GPR119, a potential drug target for metabolic disorder.
    Zhang S; Ma Y; Li J; Ma J; Yu B; Xie X
    Proc Natl Acad Sci U S A; 2014 Oct; 111(40):14571-6. PubMed ID: 25246581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity.
    Overton HA; Fyfe MC; Reynet C
    Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S76-81. PubMed ID: 18037923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?
    Hodge RJ; Nunez DJ
    Diabetes Obes Metab; 2016 May; 18(5):439-43. PubMed ID: 26818602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Mechanisms of the Anti-Obesity and Anti-Diabetic Properties of Flavonoids.
    Kawser Hossain M; Abdal Dayem A; Han J; Yin Y; Kim K; Kumar Saha S; Yang GM; Choi HY; Cho SG
    Int J Mol Sci; 2016 Apr; 17(4):569. PubMed ID: 27092490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging roles of GPER in diabetes and atherosclerosis.
    Barton M; Prossnitz ER
    Trends Endocrinol Metab; 2015 Apr; 26(4):185-92. PubMed ID: 25767029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical therapy for the patient with obesity.
    Bray GA; Ryan DH
    Circulation; 2012 Apr; 125(13):1695-703. PubMed ID: 22474312
    [No Abstract]   [Full Text] [Related]  

  • 9. Diabetes mellitus, inflammation, obesity: proposed treatment pathways for current and future therapies.
    Sonnett TE; Levien TL; Gates BJ; Robinson JD; Campbell RK
    Ann Pharmacother; 2010 Apr; 44(4):701-11. PubMed ID: 20233909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141.
    Bryzgalova G; Effendic S; Khan A; Rehnmark S; Barbounis P; Boulet J; Dong G; Singh R; Shapses S; Malm J; Webb P; Baxter JD; Grover GJ
    J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):262-7. PubMed ID: 18621127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nomilin as an anti-obesity and anti-hyperglycemic agent.
    Sato R
    Vitam Horm; 2013; 91():425-39. PubMed ID: 23374727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compound and compositions as TGR5 agonists: WO2012082947.
    Raval S
    Expert Opin Ther Pat; 2013 Apr; 23(4):531-6. PubMed ID: 23409864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic diseases.
    Balfe A; Perry L
    IDrugs; 2006 Nov; 9(11):754-5. PubMed ID: 17096291
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacological and surgical treatments for obesity.
    DeWald T; Khaodhiar L; Donahue MP; Blackburn G
    Am Heart J; 2006 Mar; 151(3):604-24. PubMed ID: 16504622
    [No Abstract]   [Full Text] [Related]  

  • 15. Protein tyrosine phosphatase 1B inhibitors for the treatment of type 2 diabetes and obesity: recent advances.
    Harley EA; Levens N
    Curr Opin Investig Drugs; 2003 Oct; 4(10):1179-89. PubMed ID: 14649209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural Products Modulating Autophagy Pathway Against the Pathogenesis of Diabetes Mellitus.
    Li L; Qi J; Li H
    Curr Drug Targets; 2019; 20(1):96-110. PubMed ID: 30047328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation effects of TZQ-F on adipocyte differentiation and insulin action.
    Nan Xia J; Qin Zhang D; Du J; Wen J
    J Ethnopharmacol; 2013 Nov; 150(2):692-9. PubMed ID: 24095827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early pharmacological intervention in newly diagnosed metabolic syndrome and type 2 diabetes.
    Naruszewicz M
    Przegl Lek; 2006; 63 Suppl 4():7-8. PubMed ID: 16967707
    [No Abstract]   [Full Text] [Related]  

  • 19. Mushrooms of the Genus
    Wińska K; Mączka W; Gabryelska K; Grabarczyk M
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31717970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Obesity Effects of Medicinal and Edible Mushrooms.
    Ganesan K; Xu B
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30400600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.